eLetters to:

REVIEW ARTICLES: Mark Lebwohl, Lily Clark, and Jacob Levitt Therapy for Head Lice Based on Life Cycle, Resistance, and Safety Considerations Pediatrics 2007; 119: 965-974 [Abstract] [Full text] [PDF]

eLetters: Submit a response to this article

eLetters published:

Homonyms

Leonard Levy, M.D.   (4 May 2007)

an ad disguised as a review article

Kelly D. Young   (18 June 2007)

Homonyms 4 May 2007
Leonard Levy, M.D., Pediatrician in private practice N/A Send letter to journal: Re: Homonyms llevy1{at}twcny.rr.com Leonard Levy, M.D.	"The former faired worse than malathion applied at days 0 and 7,36 whereas the latter faired better compared with malathion or permethrin single-use therapy. " I don't think the authors intended to use the word "fair." I'm also fairly sure that Pediatrics employs editors. Leonard Levy, MD 6836 E. Genesee Street Fayetteville, NY 13066 Conflict of Interest: None declared
an ad disguised as a review article 18 June 2007
Kelly D. Young, Pediatric Emergency Physician David Geffen School of Medicine, Harbor-UCLA Medical Center Send letter to journal: Re: an ad disguised as a review article kyoung{at}emedharbor.edu Kelly D. Young	I was astounded to read this obviously biased article in Pediatrics. While it is entirely possible that Ovide should be the preferred treatment for head lice, I am unable to discern what information to trust at face value, since the article is written by someone who is a major shareholder and vice president of the company that makes and sells Ovide for $125 per bottle. I am surprised that Pediatrics allowed a pharmaceutical company to basically write a 9 page ad in the guise of a review article. As I first read the article, I thought to myself, "Wow, this sounds like someone involved with Ovide wrote it," but I never thought that would actually be true. AFTER I read the article, I looked at the title and saw the disclosure in itsy bitsy font, and realized that I had just wasted my time reading this article. Conflict of Interest: None declared